#600: From Breakthrough to Life: Engineered T-Cells, Patients, and the Future of Biotech

Wednesday, June 17, 2026 8:00 AM to 9:00 AM · 1 hr. (America/New_York)
114
00: Plenary05: PersonalizedMed-ComboProd-Diagnostics08: RegPolicy-Strategy-GlobalCollaboration18: Lift-Series

Information

Following a keynote presentation by Bruce Levine on the future of genetically engineered T-cells for human therapeutics, sit down with Bruce and Brad Watts for a fireside chat. Through scientific, policy, and patient lenses, the session will examine what it takes to translate high-risk science into sustainable therapies, and what that implies for regulators, payers, sponsors, and technology partners.
Session Level
Intermediate
Featured Topics
Biotech-ClinTech-PathwayStudent and Early Career PathwayTherapeutic Pathways
Learning Objectives
Describe how advances in engineered T-cells, including CAR-T, are reshaping expectations for cancer treatment and the broader pipeline; Identify scientific, regulatory, and system conditions needed to translate high-risk engineered innovations into equitable, scalable patient benefit; Discuss how real patient and family experiences inform future strategies for regulators, payers, sponsors, researchers, and technology partners developing next-generation cell therapies.

Log in

See all the content and easy-to-use features by logging in or registering!